FDA Inspection
Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc. – FDA Inspection, Jul 3, 2018
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Pharmaceuticals, Inc., with an inspection on July 3, 2018, issued by the New England District Office, covering human drugs.
View Company Profile
ID · e785d17b-1b62-499e-b933-e90b9174d6e7
Inspection Facts
- Inspection number
- 1066876
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Boehringer Ingelheim Pharmaceuticals, Inc.
19| Date | Classification | Office | Project area |
|---|---|---|---|
| August 25, 2026 | Not classified | New England District Office | |
| September 11, 2025 | VAI | New England District Office | Bioresearch Monitoring: Human Drugs |
| May 2, 2024 | Not classified | New England District Office | |
| September 22, 2023 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| December 12, 2019 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Boehringer Ingelheim Pharmaceuticals, Inc.
- FDA Inspection 1334848 - 2026-08-25
- FDA Inspection 1281125 - 2025-09-11
- FDA Inspection 1235545 - 2024-05-02
- FDA Inspection 1219707 - 2023-09-22
- FDA Inspection 1112627 - 2019-12-12
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.